Patents Assigned to Arch Development
  • Patent number: 6524832
    Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
    Type: Grant
    Filed: August 19, 1994
    Date of Patent: February 25, 2003
    Assignee: Arch Development Corporation
    Inventors: Donald Kufe, Ralph R. Weichselbaum
  • Patent number: 6511603
    Abstract: An extractant medium for extracting alkaline earth cations from an aqueous acidic sample solution is described as are a method and apparatus for using the same. The separation medium is free of diluent, free-flowing and particulate, and comprises a Crown ether that is a 4,4′(5′)[C4-C8-alkylcyclohexano]18-Crown-6 dispersed on an inert substrate material.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: January 28, 2003
    Assignee: Arch Development Corp.
    Inventors: Mark Dietz, E. Philip Horwitz
  • Patent number: 6511828
    Abstract: A new family of proteins having structural similarity to the baculovirus inhibitor of apoptosis protein (iap) are described. These ilp's (iap-like proteins) are distinguished by the presence of a RING finger domain and three baculovirus iap-like repeat motifs. Exemplified are sequences from Drosophila and human. Methods for the use of these proteins, and nucleic acids coding therefor, are provided. These methods include both the inhibition and stimulation of apoptosis in target cells.
    Type: Grant
    Filed: May 31, 1996
    Date of Patent: January 28, 2003
    Assignee: Arch Development Corporation
    Inventors: Craig B. Thompson, Colin S. Duckett
  • Patent number: 6506378
    Abstract: The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: January 14, 2003
    Assignee: Arch Development Corporation
    Inventor: Un Jung Kang
  • Publication number: 20020192822
    Abstract: The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an a4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.
    Type: Application
    Filed: April 2, 2001
    Publication date: December 19, 2002
    Applicant: Arch Development Corporation
    Inventors: Rosario Leopardi, Bernard Roizman
  • Patent number: 6488859
    Abstract: A cross-linked water-insoluble ion exchange resin comprised of polymerized monomers having a phenyl ring is disclosed. A contemplated resin contains (i) polymerized phenyl ring-containing monomers having a phosphonic acid ligand linked to the phenyl ring, (ii) about 2 to about 5 millimoles per gram (mmol/g) of phosphorus as phosphonic acid ligands, and (iii) a sufficient amount of a sulfonic acid ligand such that the ratio of mmol/g of phosphonic acid to mmol/g sulfonic acid is up to 3:1. A process for removing polyvalent metal cations from aqueous solution, and a process for removing iron(III) cations from acidic copper(II) cation-containing solutions that utilize the contemplated resin or other resins are disclosed.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: December 3, 2002
    Assignees: Arch Development Corp, The University of Tennessee Research Corp
    Inventors: Spiro Alexandratos, Christopher A. Shelley, E. Philip Horwitz, Renato Chiarizia, Michael J. Gula, Sui Xue, James T. Harvey
  • Patent number: 6486170
    Abstract: A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor &agr; (TNF) gene. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, as well as the subsequent activation of protein kinase C and TNF gene expression. These phospholipase A2 inhibitors may be used to ameliorate the adverse-effects of radiotherapy associated with TNF production.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: November 26, 2002
    Assignee: Arch Development Corporation
    Inventors: Dennis E. Hallahan, Ralph R. Weichselbaum, Donald W. Kufe
  • Patent number: 6483934
    Abstract: A method, system, and computer product for the automated segmentation of the lung fields and costophrenic angle (CP) regions in posteroanterior (PA) chest radiographs, wherein image segmentation based on gray-level threshold analysis is performed by applying an iterative global gray-level thresholding method to a chest image based on the features of a global gray-level histogram. Features of the regions in a binary image constructed at each iteration are identified and analyzed to exclude regions external to the lung fields. The initial lung contours that result from this global process are used to facilitate a local gray-level thresholding method. Individual regions-of-interest (ROIs) are placed along the initial contour. A procedure is implemented to determine the gray-level thresholds to be applied to the pixels within the individual ROIs. The result is a binary image, from which final contours are constructed. Smoothing processes are applied, including a unique adaptation of a rolling ball method.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: November 19, 2002
    Assignee: Arch Development Corporation
    Inventors: Samuel G. Armato, III, Maryellen L. Giger, Heber MacMahon
  • Patent number: 6482934
    Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Novel amino acid sequences are shown for the amino-acid terminus and 6 interval fragments. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: November 19, 2002
    Assignee: ARCH Development Corp.
    Inventors: F. Gary Toback, John C. Lieske
  • Patent number: 6479628
    Abstract: Disclosed are purified and isolated DNA sequences encoding eukaryotic proteins possessing biological properties of inosine 5′-monophosphate dehydrogenase (“IMPDH”). Illustratively, mammalian (e.g., human) IMPDH-encoding DNA sequences are useful in transformation or transfection of host cells for the large scale recombinant production of the enzymatically active expression products and/or products (e.g., GMP) resulting from IMPDH catalyzed synthesis in cells. Vectors including IMPDH-encoding DNA sequences are useful in gene amplification procedures. Recombinant proteins and synthetic peptides provided by the invention are useful as immunological reagents and in the preparation of antibodies (including polyclonal and monoclonal antibodies) for quantitative detection of IMPDH.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: November 12, 2002
    Assignee: Arch Development Corporation
    Inventors: Frank R. Collart, Eliezer Huberman
  • Patent number: 6472157
    Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: October 29, 2002
    Assignee: Arch Development Corporation
    Inventors: Anna Di Rienzo, Lalitha Iyer, Mark J. Ratain
  • Patent number: 6470092
    Abstract: A method to determine whether a candidate abnormality in a medical digital image is an actual abnormality, a system which implements the method, and a computer readable medium which stores program steps to implement the method, wherein the method includes obtaining a medical digital image including a candidate abnormality; obtaining plural first templates and plural second templates respectively corresponding to predetermined abnormalities and predetermined non-abnormalities; comparing the candidate abnormality with the obtained first and second templates to derive cross-correlation values between the candidate abnormality and each of the obtained first and second templates; determining the largest cross-correlation value derived in the comparing step and whether the largest cross-correlation value is produced by comparing the candidate abnormality with the first templates or with the second templates; and determining the candidate abnormality to be an actual abnormality when the largest cross-correlation val
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: October 22, 2002
    Assignee: Arch Development Corporation
    Inventors: Qiang Li, Shigehiko Katsuragawa, Kunio Doi
  • Patent number: 6467916
    Abstract: A non-imaging optical system for operating on light using broken symmetry reflector surfaces (30). The theoretical upper limit for concentration of direct solar radiation at low latitudes with stationary concentrators is determined from the projected solid angle sampled by the apparent motion of the sun. Based on the fact that the solar radiation is not uniformly distributed within this projected solid angle, we derive higher concentrations which apply when rejecting the lower density radiation. Trough type systems, which have translational symmetry, cannot be ideal stationary concentrators. Efficiency is improved by using broken symmetry for surfaces of the reflector (30) and the light source or concentrator. We note that what applies to concentrators applies equally to reflectors for illumination.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: October 22, 2002
    Assignee: Arch Development Corp.
    Inventor: Roland Winston
  • Patent number: 6466689
    Abstract: A system and method for digital imaging. A digital radiological image of a subject is obtained having at least one low density region. The image is processed using first weighting factors in the at least one low density region of the digital image and second weighting factors smaller than the first weighting factors in regions of the digital image other than the at least one low density region. A processed digital image is obtained and a representation of the processed digital image is produced. In the processing of the image, unsharp mask filtering is employed using a processing curve having maximum unsharp mask filtering in the at least one low density region of the digital image and a constant amount of unsharp mask filtering less than the maximum unsharp mask filtering in the regions of the image other than the low density regions.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: October 15, 2002
    Assignee: Arch Development Corp.
    Inventor: Heber MacMahon
  • Patent number: 6442287
    Abstract: An automated method, storage medium, and system for analyzing bone. Digital image data corresponding to an image of the bone are obtained. Next there is determined, based on the digital images, a measure of bone mineral density (BMD) and at least one of a measure of bone geometry, a Minkowski dimension, and a trabecular orientation. The strength of the bone is estimated based upon the measure of BMD and at least one of the measure of bone geometry, the Minkowski dimension, and the trabecular orientation. To improve bone texture analysis, the present invention also provides a novel automated method, storage medium, and system in which digital image data corresponding to an image of the bone is obtained, and a region of interest (ROI) is selected within the bone. A fractal characteristic of the image data within the ROI using an artificial neural network is extracted. The strength of the bone is estimated based at least in part on the extracted fractal characteristic.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 27, 2002
    Assignee: Arch Development Corporation
    Inventors: Chunsheng Jiang, Michael R. Chinander, Maryellen L. Giger
  • Publication number: 20020115097
    Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.
    Type: Application
    Filed: February 1, 2002
    Publication date: August 22, 2002
    Applicant: Arch Development Corporation
    Inventors: Anna Di Rienzo, Lalitha Iyer, Mark J. Ratain
  • Patent number: 6436907
    Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: August 20, 2002
    Assignee: Arch Development Corporation
    Inventors: Jeffrey M. Leiden, Eliav Barr
  • Patent number: 6436945
    Abstract: The present invention provides AGT inactivating compounds, for example, substituted O6-benzyl-8-aza-guanines of the formula wherein R, for example, is pivaloyloxymethyl as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: August 20, 2002
    Assignees: The United States of America as represented by the of Health and Human Services, The Penn State Research Foundation, Arch Development Corporation
    Inventors: Robert C. Moschel, Anthony E. Pegg, M. Eileen Dolan, Mi-Young Chae
  • Patent number: 6429359
    Abstract: A genetic construct encoding a fusion protein including endogluconase E1 and a transit peptide is used to transform plants. The plants produce cellulase by expressing the genetic construct. The cellulase is targeted to plastids and can be collected and purified.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: August 6, 2002
    Assignee: ARCH Development Corporation
    Inventor: Gayle Lamppa
  • Patent number: 6426351
    Abstract: Chelerythrine is an effective inhibitor of solid tumor growth and is extremely cytotoxic in combination with chemotherapeutic agents that directly damage DNA.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: July 30, 2002
    Assignees: Dana-Farber Cancer, Inc., Arch Development Corporation
    Inventors: Ralph R. Weichselbaum, Donald W. Kufe, Steven J. Chmura, Mary E. Dolan